Clinical Trials Arena reports reduced tau in a Phase I/IIa study of Arrowhead’s Alzheimer’s disease therapy. The company is shifting testing from healthy volunteers to participants with Alzheimer’s disease.
Trial resultsTrial conduct and operationsAI summary
Read at Clinical Trials Arena